{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:47Z","timestamp":1782337247551,"version":"3.54.5"},"reference-count":32,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Newly diagnosed mantle cell lymphoma (MCL) is commonly treated with rituximab (R), combined with anthracycline-based chemotherapy, with or without autologous stem cell transplantation (ASCT). Although R maintenance (RM) in clinical trials has been shown to prolong overall survival (OS), its impact at the population level remains largely unknown. This study evaluated the effect of RM on the outcome of patients with MCL. Patients aged \u226518 years, who were diagnosed with MCL between 1989 and 2020 were identified using the Netherlands Cancer Registry and were categorized into periods that reflected R and RM implementation (1989-2000, 2001-2014, 2015-2020). The treatment strategies were categorized as R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone); R-CHOP, followed by high-dose cytarabine (intensive) and ASCT; and other. The primary end point was 5-year OS. A multivariable analysis (MVA) was performed using Cox regression. Among 4751 patients, the 5-year relative survival (RS) improved from 38% (1989-2000) to 47% (2001-2014) and 60% (2015-2020) (P&amp;lt; .01), irrespective of age (\u226465 years: 32% vs &amp;gt;65 years: 20% increase over time). Patients with progression within 12 months had a 2-year OS rate of 25%. Since 2014, RM implementation reached 80% in younger patients and 50% in older patients. RM was associated with improved OS, especially for patients in partial remission (PR) after induction treatment with R-CHOP. In the MVA of patients treated with R-CHOP, RM was independently associated with reduced mortality (hazard ratio, 0.69; 95% confidence interval, 0.53-0.90). The RS in MCL improved by &amp;gt;20% in 30 years. Early disease progression remains associated with poor outcome. RM was associated with improved survival, especially among patients who achieved PR following R-CHOP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018667","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:23:29Z","timestamp":1770236609000},"page":"2916-2924","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Impact of rituximab maintenance on survival in patients with mantle cell lymphoma: a population-based cohort study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0759-2966","authenticated-orcid":false,"given":"Floriske","family":"Stedema","sequence":"first","affiliation":[{"name":"1Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-4810","authenticated-orcid":false,"given":"Mirian","family":"Brink","sequence":"additional","affiliation":[{"name":"2Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francien","family":"Huisman","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Treant Emmen, Emmen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos","family":"van Rijn","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Frisius Medical Center Leeuwarden, Leeuwarden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniko","family":"Sijs- Szabo","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Nijhof","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine-Hematology, St. Antonius Hospital, Nieuwegein, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-1050","authenticated-orcid":false,"given":"Arjan","family":"Diepstra","sequence":"additional","affiliation":[{"name":"7Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Vergote","sequence":"additional","affiliation":[{"name":"8Department of Hematology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7327-7834","authenticated-orcid":false,"given":"Gwendolyn","family":"van Gorkum","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs","family":"Flinsenberg","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van Meerten","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1014-0918","authenticated-orcid":false,"given":"Jeanette","family":"Doorduijn","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9828-9460","authenticated-orcid":false,"given":"Wouter","family":"Plattel","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-2873","authenticated-orcid":false,"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"8","key":"2026051211563842300_bib1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"2026051211563842300_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/17474086.2018.1449635","article-title":"Does maintenance therapy have a role in mantle cell lymphoma treatment?","volume":"11","author":"Parrott","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2026051211563842300_bib3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"9873","key":"2026051211563842300_bib4","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"10044","key":"2026051211563842300_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"suppl_4","key":"2026051211563842300_bib6","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"10441","key":"2026051211563842300_bib7","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"issue":"13","key":"2026051211563842300_bib8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2026051211563842300_bib9","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1097\/HS9.0000000000000136","article-title":"Maintenance treatment for patients with mantle cell lymphoma: a systematic review and meta-analysis of randomized trials","volume":"2","author":"Vidal","year":"2018","journal-title":"Hemasphere"},{"issue":"3","key":"2026051211563842300_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026051211563842300_bib11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026051211563842300_bib12","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3324\/haematol.2022.282252","article-title":"Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis","volume":"108","author":"Di","year":"2023","journal-title":"Haematologica"},{"issue":"11","key":"2026051211563842300_bib13","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/annonc\/mdv364","article-title":"Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"26","author":"Graf","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"2026051211563842300_bib14","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.bbmt.2017.07.006","article-title":"Long-term results of high-dose therapy and autologous stem cell transplantation for mantle cell lymphoma: effectiveness of maintenance rituximab","volume":"23","author":"Mei","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"2026051211563842300_bib15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.23.01586","article-title":"Long-term follow-up of rituximab maintenance in young patients with mantle-cell lymphoma included in the LYMA trial: a LYSA study","volume":"42","author":"Sarkozy","year":"2024","journal-title":"J Clin Oncol"},{"issue":"26","key":"2026051211563842300_bib16","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"2026051211563842300_bib17","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.23.01030","article-title":"National estimates of the participation of patients with cancer in clinical research studies based on Commission on Cancer accreditation data","volume":"42","author":"Unger","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026051211563842300_bib18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ije\/22.3.369","article-title":"Completeness of cancer registration in Limburg, the Netherlands","volume":"22","author":"Schouten","year":"1993","journal-title":"Int J Epidemiol"},{"issue":"6","key":"2026051211563842300_bib19","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"issue":"5","key":"2026051211563842300_bib20","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026051211563842300_bib21","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026051211563842300_bib22","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"2026051211563842300_bib23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2021.12.037","article-title":"Characteristics of clinical trials for haematological malignancies from 2015 to 2020: a systematic review","volume":"167","author":"Wesson","year":"2022","journal-title":"Eur J Cancer"},{"issue":"5","key":"2026051211563842300_bib24","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.23.00899","article-title":"Predictive value of minimal residual disease for efficacy of rituximab maintenance in mantle cell lymphoma: results from the European Mantle Cell Lymphoma Elderly trial","volume":"42","author":"Hoster","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026051211563842300_bib25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"16","key":"2026051211563842300_bib26","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/bloodadvances.2023009804","article-title":"Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed\/refractory mantle cell lymphoma","volume":"7","author":"Villa","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2026051211563842300_bib27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjh.18519","article-title":"Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study","volume":"202","author":"Hess","year":"2023","journal-title":"Br J Haematol"},{"issue":"10277","key":"2026051211563842300_bib28","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"2026051211563842300_bib29","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026051211563842300_bib30","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"2026051211563842300_bib31","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026051211563842300_bib32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2916\/2515778\/blooda_adv-2025-018667-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2916\/2515778\/blooda_adv-2025-018667-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:56:46Z","timestamp":1778601406000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/2916\/566428\/Impact-of-rituximab-maintenance-on-survival-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018667","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,4,29]]}}}